Myo-inositol During Pregnancy to Prevent Gestational Diabetes
Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial
Tufts Medical Center
40 participants
Mar 1, 2025
INTERVENTIONAL
Conditions
Summary
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM). This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
Eligibility
Inclusion Criteria9
- Singleton gestations
- Women aged > 18 years and < 45 years
- Recruited before 16 weeks gestation
- Obese (pre-pregnancy BMI ≥ 30)
- Receiving prenatal care at Tufts Medical Center
- Planning to give birth at Tufts Medical Center
- Can tolerate glucose tolerance test
- Willing and able to wear CGM
- Willing and able to sign informed consent
Exclusion Criteria8
- Multiple gestation
- Preexisting diabetes
- Taking medications that impact body weight or metabolism (eg metformin)
- Inability to tolerate glucose tolerance test
- Adults unable to consent (cognitively impaired adults)
- Wards of the state
- Non-viable neonates
- Neonates of uncertain viability
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients would begin taking myoinositol upon recruitment
Patients would begin taking placebo upon recruitment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06575868